Impact of Type of Hypomethylating Agent (HMA) Used on Outcomes of Patients (Pts) with Higher-Risk Myelodysplastic Syndromes/Neoplasms (HR-MDS) - a Large, Multicenter, Retrospective Analysis

被引：0

作者：

Bewersdorf, Philipp ^{[1
,2
]}

Kewan, Tariq ^{[3
]}

Blaha, Ondrej ^{[4
,5
,6
]}

Stahl, Maximilian ^{[7
]}

Al Ali, Najla H. ^{[8
]}

DeZern, Amy E. ^{[9
]}

Sekeres, Mikkael A. ^{[10
]}

Uy, Geoffrey L. ^{[11
]}

Carraway, Hetty E. ^{[12
]}

Desai, Pinkal ^{[13
]}

Griffiths, Elizabeth A. ^{[14
]}

Stein, Eytan M. ^{[15
]}

Brunner, Andrew M. ^{[16
]}

McMahon, Christine M. ^{[17
]}

Zeidner, Joshua F. ^{[18
]}

Savona, Michael R. ^{[19
]}

Stempel, Jessica M. ^{[20
]}

Chandhok, Namrata Sonia ^{[21
]}

Ramaswamy, Rahul ^{[22
]}

Roboz, Gail J. ^{[23
]}

Rolles, Benjamin ^{[24
]}

Wang, Eunice S. ^{[14
]}

Harris, Amyah C. ^{[25
]}

Amaya, Maria L. ^{[26
]}

Hawkins, Hayley ^{[27
]}

Grenet, Justin ^{[28
]}

Gurnari, Carmelo ^{[29
]}

Shallis, Rory M. ^{[30
]}

Xie, Zhuoer ^{[31
]}

Maciejewski, Jaroslaw P. ^{[29
]}

Sallman, David A. ^{[31
]}

Della Porta, Matteo Giovanni ^{[32
]}

Komrokji, Rami S. ^{[8
]}

Zeidan, Amer M. ^{[33
,34
]}

机构：

[1] Mem Sloan Kettering Canc Ctr, New York, NY USA

[2] Yale Univ, Sect Hematol, Dept Med, New Haven, CT USA

[3] Yale Univ, Sect Hematol, Dept Internal Med, New Haven, CT USA

[4] Yale Univ, Sch Publ Hlth, Dept Biostat, New Haven, CT USA

[5] Yale Univ, Sch Publ Hlth, Yale Ctr Analyt Sci, New Haven, CT USA

[6] Yale Univ, Yale Canc Ctr, New Haven, CT USA

[7] Dana Farber Inst, Boston, MA USA

[8] H Lee Moffitt Canc Ctr & Res Inst, Dept Malignant Hematol, Tampa, FL USA

[9] Johns Hopkins Univ, Baltimore, MD USA

[10] Univ Miami, Sylvester Canc Ctr, Miami, FL USA

[11] Washington Univ, Div Oncol, Sch Med, St Louis, MO USA

[12] Cleveland Clin, Taussig Canc Inst, Dept Hematol & Med Oncol, Leukemia Program, Cleveland, OH USA

[13] Weill Cornell Med, New York, NY USA

[14] Roswell Park Comprehens Canc Ctr, Buffalo, NY USA

[15] Mem Sloan Kettering Canc Ctr, Leukemia Serv, New York, NY USA

[16] Dana Farber Canc Inst, Div Hematol Oncol, Boston, MA USA

[17] Univ Colorado, Div Hematol, Sch Med, Aurora, CO USA

[18] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC USA

[19] Vanderbilt Univ, Vanderbilt Ingram Canc Ctr, Med Ctr, Nashville, TN USA

[20] Yale Sch Med, Sect Hematol, Dept Internal Med, New Haven, CT USA

[21] Univ Miami, Div Hematol, Miller Sch Med, Sylvester Comprehens Canc Ctr, Miami, FL USA

[22] Washington Univ, St Louis, MO USA

[23] New York Presbyterian Hosp, New York, NY USA

[24] Harvard Med Sch, Brigham & Womens Hosp, Boston, MA USA

[25] Dana Farber Canc Inst, Boston, MA USA

[26] Univ Colorado, Div Hematol, Aurora, CO USA

[27] Vanderbilt Univ, Med Ctr, Nashville, TN USA

[28] Weill Cornell, New York, NY USA

[29] Cleveland Clin, Taussig Canc Inst, Dept Translat Hematol & Oncol Res, Cleveland, OH USA

[30] Yale Univ, Yale Sch Med, Sect Hematol, Dept Internal Med, New Haven, CT USA

[31] H Lee Moffitt Canc Inst, Tampa, FL USA

[32] IRCCS, Ctr Canc, Humanitas Res Hosp, Milan, Italy

[33] Yale Canc Ctr, Dept Internal Med, New Haven, CT USA

[34] Smilow Canc Hosp, New Haven, CT USA

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-178728

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：8

共 50 条

[41] Sabatolimab (MBG453) Combination Treatment Regimens for Patients With Higher-Risk Myelodysplastic Syndromes (HR-MDS): The Myelodysplastic Syndromes Studies in the STIMULUS Immuno-Myeloid Clinical Trial Program
Zeidan, Amer M.
Al-Kali, Aref
Borate, Uma
Cluzeau, Thomas
DeZern, Amy E.
Esteve, Jordi
Giagounidis, Aristoteles
Kobata, Krissy
Lyons, Roger
Platzbecker, Uwe
Sallman, David A.
Santini, Valeria
Sanz, Guillermo F.
Sekeres, Mikkael A.
Wei, Andrew H.
Xiao, Zhijian
Van Hoef, Marlies
Nourry-Boulot, Claire
Sadek, Islam
Ma, Fei
Iordan, Angelica
Sabo, John
Garcia-Manero, Guillermo
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S317 - S317
[42] The Effects of Continued Azacitidine (AZA) Treatment Cycles on Response in Higher-Risk Patients (Pts) with Myelodysplastic Syndromes (MDS)
Silverman, Lewis R.
Fenaux, Pierre
Mufti, Ghulam J.
Santini, Valeria
Hellstrom-Lindberg, Eva
Gattermann, Norbert
Sanz, Guillermo
List, Alan F.
Gore, Steven D.
Seymour, John F.
Backstrom, Jay
McKenzie, David
Beach, C. L.
BLOOD, 2008, 112 (11) : 91 - 91
[43] INSPIRE: A randomized phase III trial of intravenous rigosertib in patients with higher-risk myelodysplastic syndromes (HR-MDS) after failure of hypomethylating agents (HMAs) Study design informed by subgroup analyses of ONTIME.
Garcia-Manero, Guillermo
Al-Kali, Aref
Baer, Maria R.
Robor, Gail J.
Platzbecker, Uwe
Kambhampati, Suman
Godley, Lucy A.
Collins, Robert
Shammo, Jamile M.
Santini, Valeria
Raza, Azra
Silverman, Lewis R.
Azarnia, Nozar
Fruchtman, Steven M.
Snyder, Barbara R.
Fenaux, Pierre
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[44] Does Provider Experience Treating Patients (pts) with Myelodysplastic Syndromes (MDS) Explain Duration of Hypomethylating Agent (HMA) Therapy and Overall Survival (OS)? A Large Population-Based Analysis
Zeidan, Amer M.
Hu, Xin
Zhu, Weiwei
Stahl, Maximilian
Giri, Smith
Huntington, Scott F.
Wang, Rong
Podoltsev, Nikolai A.
Gore, Steven D.
Ma, Xiaomei
Davidoff, Amy J.
BLOOD, 2018, 132
[45] Outcome of Patients (pts) with Low and Intermediate-1 Risk Myelodysplastic Syndrome (MDS) After Hypomethylating Agent (HMA) Failure.
Jabbour, Elias J.
Daver, Naval G.
Dong, Tina
Kadia, Tapan M.
O'Brien, Susan
Cortes, Jorge E.
Ravandi, Farhad
Pemmaraju, Naveen
Ghanem, Hady
Faderl, Stefan
Borthakur, Gautam
Kantarjian, Hagop M.
Garcia-Manero, Guillermo
BLOOD, 2012, 120 (21)
[46] Overall Survival and Subgroup Analysis from a Randomized Phase III Study of Intravenous Rigosertib Versus Best Supportive Care (BSC) in Patients (pts) with Higher-Risk Myelodysplastic Syndrome (HR-MDS) after Failure of Hypomethylating Agents (HMAs)
Garcia-Manero, Guillermo
Fenaux, Pierre
Al-Kali, Aref
Baer, Maria R.
Sekeres, Mikkael A.
Roboz, Gail J.
Gaidano, Gianluca
Scott, Bart L.
Greenberg, Peter L.
Platzbecker, Uwe
Steensma, David P.
Kambhampati, Suman
Kreuzer, Karl-Anton
Godley, Lucy A.
Collins, Robert
Atallah, Ehab
Wilhelm, Francois
Wilhelm, Isabelle E.
Azarnia, Nozar
Maniar, Manoj
Silverman, Lewis R.
BLOOD, 2014, 124 (21)
[47] Clinical Outcome of 40 Patients with Higher-Risk Myelodysplastic Syndromes (MDS) after Treatment with Hypomethylating Agents: a Matched-Pairs Analysis.
Nachtkamp, Kathrin
Strupp, Corinna
Kuendgen, Andrea
Gattermann, Norbert
Haas, Rainer
Germing, Ulrich
BLOOD, 2008, 112 (11) : 929 - 929
[48] Safety, Pharmacodynamic, and Anti-Tumor Activity of SL-172154 As Monotherapy and in Combination with Azacitidine (AZA) in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and Higher-Risk Myelodysplastic Syndromes/Neoplasms (HR-MDS) Patients (pts)
Daver, Naval
Stein, Anthony Selwyn
Bixby, Dale
Chai-Ho, Wanxing
Zeidner, Joshua F.
Maher, Keri
Stevens, Don A.
Stahl, Maximilian
Yee, Karen
Curran, Emily K.
Ito, Sawa
Sochacki, Andrew
Sallman, David A.
Hernandez, Robert
Metenou, Simon
Ma, Bo
Kato, Kazunobu
Zeidan, Amer M.
BLOOD, 2023, 142
[49] A SYSTEMATIC LITERATURE REVIEW (SLR) OF THE CLINICAL EFFICACY AND SAFETY EVIDENCE ASSOCIATED WITH TREATMENT OF PATIENTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROME (HR-MDS)
Papadakis-Sali, A.
Bobrowska, A.
Shaw, S.
Radford, M.
Estrella, Sabate E. J.
Asukai, Y.
VALUE IN HEALTH, 2023, 26 (12) : S18 - S19
[50] Impact of Cytogenetic Abnormalities and Cytogenetic Response to Hypomethylating Agents (HMAs) in Patients (pts) with Lower Risk Myelodysplastic Syndromes (MDS)
Montalban-Bravo, Guillermo
Carcia-Manero, Guillermo
Short, Nicholas J.
Sasaki, Koji
Sekeres, Mikkael A.
Komrokji, Rami S.
Steensma, David P.
DeZern, Amy E.
Roboz, Gail J.
Kadia, Tapan
Borthakur, Gautam
DiNardo, Courtney
Miller, Darla
Estrov, Zeev
Pemmaraju, Naveen
Daver, Naval
Konopleva, Marina
Cortes, Jorge E.
Kantarjian, Hagop M.
Jabbour, Elias
BLOOD, 2015, 126 (23)

← 1 2 3 4 5 →